Construction and production of Foxp3- Fc (IgG) DNA vaccine/fusion protein

Avicenna Journal of Medical Biotechnology

Volumn 8, Issue 2, 2016, Pages 57-64

  Mousavi Niri, Neda ^a   Memarnejadian, Arash ^b   Hadjati, Jamshid ^c   Aghasadeghi, Mohammad Reza ^b   Shokri, Mehdi ^b   Pilehvar Soltanahmadi, Yones ^a   Akbarzadeh, Abolfazl ^a   Zarghami, Nosratollah ^a,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

FOXP3 protein; Fusion protein; Immunoglobulin G (IgG)

Indexed keywords

DNA LIGASE; DNA POLYMERASE; DNA VACCINE; HYBRID PROTEIN; IMIDAZOLE; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLASMID DNA; TRANSCRIPTION FACTOR FOXP3;

AGAR GEL ELECTROPHORESIS; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CANCER IMMUNOTHERAPY; CELL LYSATE; CONTROLLED STUDY; DENDRITIC CELL; ENDOCYTOSIS; ESCHERICHIA COLI; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE AMPLIFICATION; GENE EXPRESSION; HEK293 CELL LINE; IMMUNIZATION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; REGULATORY T LYMPHOCYTE; WESTERN BLOTTING;

EID: 84960096886     PISSN: 20082835     EISSN: 20084625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Powell DJ Jr, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, et al. Administration of a CD25- directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007;179(7):4919- 4928.
2. Vergati M, Schlom J, Tsang KY. The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. J Biomed Biotechnol 2011;2011:182413.
3. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007;67(1):371-380.
4. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol 2006;16(2):137-149.
5. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6(4):295-307.
6. Sheu BC, Chang WC, Huang SC. New era of regulatory T cells in tumor immunity: insights in cancer immunotherapy. J Formos Med Assoc 2010;109(1):1-3.
7. Wang HY, Wang RF. Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. Microbes Infect 2005;7(7-8):1056-1062.
8. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008;112(3):610-618.
9. Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 2009;15(3):1046- 1051.
10. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15(1):821-850.
11. Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010;33(2):211-218.
12. Lutsiak ME, Semnani RT, De Pascalis R ,Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105(7):2862-2868.
13. Rosalia RA, Štěpánek I, Polláková V, Šímová J, Bieblová J, Indrová M, et al. Administration of anti-CD25 mAb leads to impaired alpha-galactosylceramide-mediated induction of IFN-gamma production in a murine model. Immunobiology 2013;218(6):851-859.
14. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009;1174:99-106.
15. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccinemediated T-cell immunity. Blood 2007;110(9):3192- 3201.
16. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Rese 2010; 70(20):7788-7799.
17. Mattarollo SR, Steegh K, Li M, Duret H, Ngiow SF, Smyth MJ. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol Cell Biol 2013;91(1):105-114.
18. Flanagan ML, Arias RS, Hu P, Khawli LA, Epstein AL. Soluble Fc fusion proteins for biomedical research. Methods Mol Biol 2007;378:33-52.
19. Guyre PM, Graziano RF, Goldstein J, Wallace PK, Morganelli PM, Wardwell K, et al. Increased potency of Fcreceptor- targeted antigens. Cancer Immunol Immunother 1997;45(3-4):146-148.
20. You Z, Huang X, Hester J, Toh HC, Chen SY. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 2001;61(9):3704-3711.
21. Dorgham K, Abadie V, Iga M, Hartley O, Gorochov G, Combadière B. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. Vaccine 2008;26(26):3252-3260.
22. Pouriayevali MH, Memarnejadian AR, Sadat M, Zavva M, Siadat SD, Hartoonian C, et al. Designing and construction of bicistronic plasmid pIRES-Igk/mIL 18/Fc potential implications for vaccine investigations. Modares J Med Sci: Pathobiol 2011;14(2):13-23.
23. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008;42(1-3):219-232.
24. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010;2010:174378.
25. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008;9(10):776-788.
26. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008;8(2):108-120.
27. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999;189(1):169-178.
28. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998;392(6674): 408-411.
29. Deliyannis G, Boyle JS, Brady JL, Brown LE, Lew AM. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc Natl Acad Sci USA 2000;97(12):6676-6680.
30. Chambard JC, Pognonec P. A reliable way of obtaining stable inducible clones. Nucleic Acids Res 1998;26(14): 3443-3444.
31. Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J cancer 2004;111(1): 86-95.
32. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 2002;168(2):562-568.